Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Daily News

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Caitlin E. Cox

October 03, 2025

News Daily News

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

Todd Neale

June 06, 2025

News Daily News

Top General Cardiology and CVD Prevention News of 2023

Yael L. Maxwell

January 03, 2024

News Daily News

Acute MI, Stroke Risks Rise in the Months After Gout Flares

Todd Neale

August 02, 2022

News Daily News

Colchicine Lowers CVD Risk No Matter When Past ACS Occurred: LoDoCo2

Michael O'Riordan

August 26, 2021

News Daily News

Colchicine in the Crosshairs for Its High US Cost

Caitlin E. Cox

December 01, 2020

News Daily News

More Teamwork, Coordination Could Boost CV Studies in COVID-19

Shelley Wood

October 28, 2020

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

News Daily News

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

Michael O'Riordan

March 08, 2019

News Daily News

All-Cause Death Not Increased With Febuxostat Among Medicare Patients With Gout

Caitlin E. Cox

June 19, 2018

News Daily News

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Michael O'Riordan

October 20, 2017

Advertisement

ACC: It’s Time for Clinicians to Address Inflammation in CVD

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

Top General Cardiology and CVD Prevention News of 2023

Acute MI, Stroke Risks Rise in the Months After Gout Flares

Colchicine Lowers CVD Risk No Matter When Past ACS Occurred: LoDoCo2

Colchicine in the Crosshairs for Its High US Cost

More Teamwork, Coordination Could Boost CV Studies in COVID-19

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Recurrent Events Common Among Young Patients With CAD

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

All-Cause Death Not Increased With Febuxostat Among Medicare Patients With Gout

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content